{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:19:24Z","timestamp":1785547164647,"version":"3.56.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011404","name":"Indivior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011404","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Subst Abuse Treat Prev Policy"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Opioid Use Disorder (OUD) is a substance use disorder with a chronic course associated with comorbid mental and somatic disorders, a high burden of psychosocial problems and opioid maintenance treatment (OMT) as a standard treatment. In the US, OUD imposes a significant economic burden on society, with annual societal costs estimated at over 55 billion dollars. Surprisingly, in Europe and especially in Germany, there is currently no detailed information on the healthcare costs of patients with OUD. The goal of the present research is to gather cost information about OUD patients in OMT with a focus on maintenance medication and relapses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analysed health claims data of four million persons covered by statutory health insurance in Germany, applying a cost-of-illness approach and aimed at examining the direct costs of OMT patients in Germany. Patients with an ICD-10 code F11.2 and at least one claim of an OMT medication were stratified into the treatment groups buprenorphine, methadone or levomethadone, based on the first prescription in each of the follow-up years. Costs were stratified for years with and without relapses. Group comparisons were performed with ANOVA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We analysed 3165 patient years, the total annual sickness funds costs were on average 7470 \u20ac per year and patient. Comparing costs of levomethadone (8400 \u20ac, SD: 11,080 \u20ac), methadone (7090 \u20ac, SD: 10,900 \u20ac) and buprenorphine (6670 \u20ac, SD: 7430 \u20ac) revealed significant lower costs of buprenorphine compared to levomethadone (<jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.0001). In years with relapses, costs were higher than in years without relapses (8178 \u20ac vs 7409 \u20ac; SD: 11,622, resp. 10,378 \u20ac). In years with relapses, hospital costs were the major cost driver.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The present study shows the costs of OUD patients in OMT for the first time with a German dataset. Healthcare costs for patients with an OUD in OMT are associated with more than two times the cost of an average German patients. Preventing relapses might have significant impact on costs. Patients in different OMT were dissimilar which may have affected the cost differences.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13011-019-0247-9","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T19:03:26Z","timestamp":1576523006000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Opioid use disorder in Germany: healthcare costs of patients in opioid maintenance treatment"],"prefix":"10.1186","volume":"14","author":[{"given":"Jens","family":"Reimer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Vogelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Tr\u00fcmper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Scherbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,16]]},"reference":[{"key":"247_CR1","first-page":"657","volume":"12","author":"H Birnbaum","year":"2011","unstructured":"Birnbaum H, White A, Schiller M, Waldman T, Cleveland J, Setnik B, et al. Societal costs of opioid abuse, dependence, and misuse in the United States. Value Heal. 2011;12:657\u201367.","journal-title":"Value Heal"},{"key":"247_CR2","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1097\/MLR.0000000000000625","volume":"54","author":"CS Florence","year":"2016","unstructured":"Florence CS, Zhou C, Luo F, Xu L. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care. 2016;54:901\u20136.","journal-title":"Med Care"},{"key":"247_CR3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.18553\/jmcp.2005.11.6.469","volume":"11","author":"A White","year":"2005","unstructured":"White A, Birnbaum H, Mareva M, Daher M, Vallow S, Schein J, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm. 2005;11:469\u201379.","journal-title":"J Manag Care Pharm"},{"key":"247_CR4","unstructured":"Kuhn S, Schu M, Vogt I, Schmid M, Simmedinger R, Schlanstedt G, et al. Federal model project for heroin-assisted treatment [Das bundesdeutsche Modellprojekt zur heroingest\u00fctzten Behandlung Opiatabh\u00e4ngiger - Band 3 - Psychosoziale Interventionen - Kosten und Nutzen der Behandlung - Transfer in die Versorgung]. Nomos Verlagsgesellschaft. 2008:1\u2013294."},{"key":"247_CR5","unstructured":"Federal Opium Agency. Annual report on the OMT register January 2017 [Bericht zum Substitutionsregister]. 2017."},{"key":"247_CR6","first-page":"CD002209","volume":"2","author":"R Mattick","year":"2003","unstructured":"Mattick R, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2003;2:CD002209.","journal-title":"Cochrane Database Syst Rev"},{"key":"247_CR7","doi-asserted-by":"crossref","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014.","DOI":"10.1002\/14651858.CD002207.pub4"},{"key":"247_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jama.285.1.39","volume":"285","author":"M Auriacombe","year":"2001","unstructured":"Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA. 2001;285:45.","journal-title":"JAMA"},{"key":"247_CR9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1097\/01.jcp.0000245561.99036.49","volume":"26","author":"M Soyka","year":"2006","unstructured":"Soyka M, Apelt SM, Lieb M, Wittchen H-U. One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy. J Clin Psychopharmacol. 2006;26:657\u201360.","journal-title":"J Clin Psychopharmacol"},{"key":"247_CR10","first-page":"1","volume":"11","author":"M Connock","year":"2007","unstructured":"Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor R. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess (Rockv). 2007;11:1\u2013171 iii\u2013iv.","journal-title":"Health Technol Assess (Rockv)"},{"key":"247_CR11","unstructured":"Hancock C, Menega H, King N, Andrilla H, E L, Schou P. National Rural Health Association Policy Brief: treating the rural opioid epidemic. National Rural Health Association (NRHA); 2017. p. 1\u201313."},{"key":"247_CR12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1055\/s-0035-1562981","volume":"77","author":"E Swart","year":"2015","unstructured":"Swart E, Gothe H, Geyer S, Jaunzeme J, Maier B, Grobe T, et al. Good practice of secondary data analysis (GPS): guidelines and recommendations, third revision 2012\/2014. Das Gesundheitswes. 2015;77:120\u20136.","journal-title":"Das Gesundheitswes"},{"key":"247_CR13","doi-asserted-by":"crossref","unstructured":"Bauhoff S, Fischer L, G\u00f6pffarth D, Wuppermann AC. Plan Responses to Diagnosis- Based Payment: Evidence from Germany\u2019s Morbidity-Based Risk Adjustment. Munich; 2017. Report No.: 6507.","DOI":"10.1016\/j.jhealeco.2017.03.001"},{"key":"247_CR14","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report 2017. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); 2017."},{"key":"247_CR15","first-page":"202","volume":"13","author":"K Langer","year":"2011","unstructured":"Langer K, Wittchen H-U, B\u00fchringer G, Rehm JT. Opioid maintenance treatment of opioid dependent patients: background. Care Structure and Challenges Suchtmed. 2011;13:202\u201312.","journal-title":"Care Structure and Challenges Suchtmed"},{"key":"247_CR16","unstructured":"Erbas B, Fahrmbacher-Lutz C, Pogarell O, Stecker G, Tauber W, Wodarz N. Guideline for physicians for opioid maintanance treatment in opioid dependent patients, 4th edition [Leitfaden f\u00fcr \u00c4rzte zur substitutionsgest\u00fctzten Behandlung Opiatabh\u00e4ngiger, 4. vollst\u00e4ndig \u00fcberarbeitete Auflage]. Munich; 2018."},{"key":"247_CR17","unstructured":"German Medical Association Guideline of the German Medical Association fot the execution of opioid maintanance treatment in opioid dependent patients [Richtlinie der Bundes\u00e4rztekammer zur Durchf\u00fchrung der substitutionsgest\u00fctzten Behandlung Opioidabh\u00e4ngiger], 02.10.2017. German Medical Association; 2017. p. 1\u201319."},{"key":"247_CR18","unstructured":"National Association of Statutory Health Insurance Funds (GKV-Spitzenverband), German Pharmacists\u2019 Association (DAV). Contract on prices for compounds and preparations of compounds [Vertrag \u00fcber die Preisbildung f\u00fcr Stoffe und Zubereitungen aus Stoffen, Hilfstaxe]. Berlin, Eschborn; 2010. p. 1\u201327."},{"key":"247_CR19","first-page":"227","volume":"13","author":"H-U Wittchen","year":"2011","unstructured":"Wittchen H-U, B\u00fchringer G, Rehm JT, Soyka M, Tr\u00e4der A, Trautmann S. The social, clinical and treatment situation of opioid maintenance treatment in a prevalence sample of patients at baseline. Suchtmed. 2011;13:227\u201331.","journal-title":"Suchtmed"},{"key":"247_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.24945\/MVF.02.19.1866-0533.2093","volume":"12","author":"T Vogelmann","year":"2019","unstructured":"Vogelmann T, Schwarz R, Tr\u00fcmper D. Financing of appropriate treatment and special support of opioid dependence through the morbidity-based risk adjustment system (Morbi-RSA). Monit Versorgungsforsch. 2019;12:65\u201370.","journal-title":"Monit Versorgungsforsch"},{"key":"247_CR21","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2337\/dc17-1763","volume":"41","author":"K K\u00e4hm","year":"2018","unstructured":"K\u00e4hm K, Laxy M, Schneider U, Rogowski WH, Lhachimi SK, Holle R. Health care costs associated with incident complications in patients with type 2 diabetes in Germany. Diabetes Care. 2018;41:971\u20138.","journal-title":"Diabetes Care"},{"key":"247_CR22","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s10198-016-0858-2","volume":"18","author":"K Bode","year":"2017","unstructured":"Bode K, Vogel R, Walker J, Kr\u00f6ger C. Health care costs of borderline personality disorder and matched controls with major depressive disorder: a comparative study based on anonymized claims data. Eur J Health Econ. 2017;18:1125\u201335.","journal-title":"Eur J Health Econ"},{"key":"247_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/j.pain.0000000000001067","volume":"159","author":"W H\u00e4user","year":"2018","unstructured":"H\u00e4user W, Schubert T, Scherbaum N, T\u00f6lle T. Guideline-recommended vs high-dose long-term opioid therapy for chronic noncancer pain is associated with better health outcomes. Pain. 2018;159:85\u201391.","journal-title":"Pain"},{"key":"247_CR24","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/j.1360-0443.2009.02539.x","volume":"104","author":"PG Barnett","year":"2009","unstructured":"Barnett PG. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction. 2009;104:982\u201392.","journal-title":"Addiction"},{"key":"247_CR25","first-page":"200","volume":"63","author":"A Srivastava","year":"2017","unstructured":"Srivastava A, Kahan M, Nader M. Primary care management of opioid use disorders: abstinence, methadone, or buprenorphine-naloxone? Can Fam Physician. 2017;63:200\u20135.","journal-title":"Can Fam Physician"},{"key":"247_CR26","unstructured":"National Association of Statutory Health Insurance Pysicians. Uniform Evaluation Scale 2016 [Internet]. Available from: https:\/\/www.kbv.de\/html\/online-ebm.php"},{"key":"247_CR27","doi-asserted-by":"crossref","unstructured":"Jakovljevic M, Mi\u0458ailovic Z, Popovska Jovicic B, Canovic P, Gajovic O, Jovanovic M, et al. Assessment of viral genotype impact to the cost-effectiveness and overall costs of Care for peg-Interferon-2\u03b1 + Ribavirine treated chronic hepatitis C patients. Hepat Mon. 2013;13.","DOI":"10.5812\/hepatmon.6750"},{"key":"247_CR28","doi-asserted-by":"crossref","unstructured":"Jakovljevic M, Jovanovic M, Rancic N, Vyssoki B, Djordjevic N. LAT Software Induced Savings on Medical Costs of Alcohol Addicts\u2019 Care - Results from a Matched-Pairs Case-Control Study. Bruns H, editor. PLoS One. 2014;9:e111931.","DOI":"10.1371\/journal.pone.0111931"},{"key":"247_CR29","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00103-013-1916-x","volume":"57","author":"F Hoffmann","year":"2014","unstructured":"Hoffmann F, Bachmann CJ. Differences in sociodemographic characteristics, health, and health service use of children and adolescents according to their health insurance funds. Bundesgesundheitsblatt - Gesundheitsforsch - Gesundheitsschutz. 2014;57:455\u201363.","journal-title":"Bundesgesundheitsblatt - Gesundheitsforsch - Gesundheitsschutz"},{"key":"247_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/1099-176X(200003)3:1<11::AID-MHP66>3.0.CO;2-0","volume":"3","author":"WS Cartwright","year":"2000","unstructured":"Cartwright WS. Cost-benefit analysis of drug treatment services: review of the literature. J Ment Health Policy Econ. 2000;3:11\u201326.","journal-title":"J Ment Health Policy Econ"},{"key":"247_CR31","first-page":"5","volume":"4","author":"M Lieb","year":"2010","unstructured":"Lieb M, Wittchen H-U, Palm U, Apelt SM, Siegert J, Soyka M. Psychiatric comorbidity in substitution treatment of opioid-dependent patients in primary care: prevalence and impact on clinical features. Heroin Addict Relat Clin Probl. 2010;4:5\u201316.","journal-title":"Heroin Addict Relat Clin Probl"},{"key":"247_CR32","doi-asserted-by":"crossref","first-page":"299","DOI":"10.31887\/DCNS.2017.19.3\/msoyka","volume":"19","author":"M Soyka","year":"2017","unstructured":"Soyka M. Treatment of opioid dependence with buprenorphine: current update. Dialogues Clin Neurosci. 2017;19:299\u2013308.","journal-title":"Dialogues Clin Neurosci"}],"container-title":["Substance Abuse Treatment, Prevention, and Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-019-0247-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13011-019-0247-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-019-0247-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T15:09:27Z","timestamp":1613142567000},"score":1,"resource":{"primary":{"URL":"https:\/\/substanceabusepolicy.biomedcentral.com\/articles\/10.1186\/s13011-019-0247-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["247"],"URL":"https:\/\/doi.org\/10.1186\/s13011-019-0247-9","relation":{},"ISSN":["1747-597X"],"issn-type":[{"value":"1747-597X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"24 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was based on previously available and fully anonymized data and did not involve any new studies of human or animal subjects performed by any of the authors. Therefore, no ethics review and approval or informed consent for participants was required. However, approvals from the involved SHIs were obtained to use their data for this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Jens Reimer reports personal fees from Indivior, during the conduct of the study; personal fees from Sanofi-Aventis, personal fees from Hexal, grants and personal fees from Mundipharma, personal fees from Camurus, grants and personal fees from Indivior, outside the submitted work.Norbert Scherbaum reports personal fees from Sanofi-Aventis, personal fees from Indivior, personal fees from AbbVie, personal fees from MSD Pharma, personal fees from Mundipharma, during the conduct of the study.Tobias Vogelmann reports personal fees from Indivior, during the conduct of the study; personal fees from Indivior, outside the submitted work.Daniel Tr\u00fcmper reports personal fees from Indivior.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}